L-deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1410-1417

  Löscher, Wolfgang ^a   Lehmann, Holger ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHENOBARBITAL; SELEGILINE;

ADOLESCENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG POTENCY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SEIZURE THRESHOLD; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, GENERALIZED; MALE; MICE; MICE, INBRED STRAINS; SELEGILINE;

EID: 0030432586     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. CHAMPNEY, T. H. AND PETERSON, S. L.: Circadian, seasonal, pineal and melatonin influences on epilepsy. In Melatonin. Biosynthesis, Physiological Effects and Clinical Applications, ed. by H.-S. Yu and R. J. Reiter, pp. 478-494, CRC Press, Boca Raton, FL, 1993.
2. DOSTERT, P., STROLIN BENBDETTI, M. AND TIPTON, K. F.: New anticonvulsants with selective MAO-B inhibitory activity. Eur. J. Neuropsychopharmacol. 1: 317-319, 1991.
3. FANG, J. AND Yu, P. H.: Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33: 763-768, 1994.
4. GAÁL, J. AND HERMECZ, I.: Medicinal chemistry of present and future MAO-B inhibitors. In Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders, ed. by I. Szelenyi, pp. 75-108, Birkhäuser, Basel, 1993.
5. GERLACH, M., RIEDERER, P. AND YOUDIM, M. B. H.: The molecular pharmacology of L-deprenyl. Eur. J. Pharmacol. Mol. Pharm. 226: 97-108, 1992.
6. GERLACH, M., YOUDIM, M. B. H. AND RIEDERER, P.: Is selegiline neuroprotective in Parkinson's disease? J. Neural Trans. 41: suppl., 177-188, 1994.
7. HEINONEN, E. H., ANTTILA, M. I. AND LAMMINTAUSTA, R. A. S.: Pharmacokinetics and clinical pharmacology of selegiline. In Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders, ed. by I. Szelenyi, pp. 201-213, Birkhäuser, Basel, 1993.
8. HEINONEN, E. H. AND LAMMINTAUSTA, R.: A review of the pharmacology of selegiline. Acta Neurol. Scand. 84: 44-59, 1991.
9. KILIAN, M. AND FREY, H.-H.: Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology 12: 681-692, 1973.
10. KIMBALL, A. W., BURNETT, W. T. AND DOHERTY, D. G.: Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat. Res. 7:1-12, 1957.
11. KNOLL, J.: The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: A personal view. Pharmacol. Toxicol. 70: 317-321, 1992.
12. KNOLL, J.: The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural Transm. Gen. Sect. Suppl. 40: 69-91, 1993.
13. 3H]-PK 11195 binding sites in human epileptic hippocampus. Epilepsia 33: 610-617, 1992.
14. LITCHFIELD, J. T. AND WILCOXON, F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96: 99-113, 1949.
15. LÖSCHER, W.: Comparative assay of anticonvulsant and toxic potencies of sixteen GABAmimetic drugs. Neuropharmacology 21: 803-810, 1982.
16. LÖSCHER, W.: GABAmimetics in animal models of seizure states. In Epilepsy and GABA Receptor Agonists. Basic and Therapeutic Research, ed. by G. Bartholini, L. Bossi, K G. Lloyd and P. L. Morselli, pp. 109-119, Raven Press, New York, 1985.
17. LÖSCHER, W., HÖNACK, D. AND HASHEM, A.: Anticonvulsant efficacy of clonazepam and the β-carboline ZK 93423 during chronic treatment in amygdalakindled rats. Eur. J. Pharmacol. 148: 403-414, 1987.
18. LÖSCHER, W., FASSBENDER, C. P. AND NOLTING, B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8: 79-94, 1991a.
19. LÖSCHER, W., HÖNACK, D., FASSBENDER, C. P. AND NOLTING, B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 8: 171-189, 1991b.
20. 1A receptors. J. Pharmacol. Exp. Ther. 257: 1146-1153, 1991.
21. LÖSCHER, W. AND HÖNACK, D.: The behavioural effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215: 199-208, 1992.
22. LÖSCHER, W. AND HÖNACK, D.: Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232: 147-158, 1993.
23. LÖSCHER, W. AND HÖNACK, D.: Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy. J. Pharmacol. Exp. Ther. 274: 307-314, 1995.
24. LÖSCHER, W. AND NOLTING, B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res. 9: 1-10, 1991.
25. LÖSCHER, W. AND SCHMIDT, D.: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2: 145-181, 1988.
26. LÖSCHER, W. AND SCHMIDT, D.: Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17: 95-134, 1994.
27. MAGYAR, K, VIZI, E. S., ECSERI, Z. AND KNOLL, J.: Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinalamine (E-250). Acta Physiol. Hung. 32: 377-387, 1967.
28. MISHRA, P. K., KAHLE, E. H., BETTENDORF, A. F., DAILEY, J. W. AND JOBE, P. C.: Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe genetically epilepsy-prone rats (GEPR-9s). Life Sci. 52: 1435-1441, 1993.
29. MUKHOPADHYAY, M., UPADHYAY, S. N. AND BATTACHARYA, S. K.: Neuropharmacological studies on selective monoamine oxidase A and B inhibitors. Indian J. Exp. Biol. 28: 761-770, 1987.
30. NICKEL, B., SCHULZE, G. AND SZELENYI, I.: Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats. Neuropharmacology 29: 983-992, 1990.
31. OXENKRUG, G. F., REQUINTINA, P. J., CORREA, R. M. AND YUWILER, A.: The effect of 6-months 1-deprenyl administration on pineal MAO-A and MAO-B activity and on the content of melatonin and related indoles in aged female Fisher 344N rats. J. Neural Transm. 41: suppl., 249-252, 1994.
32. POLYMEROPOULOS, E. E.: l-Deprenyl: A unique MAO-B inhibitor. In Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders, ed. by I. Szelenyi, pp. 109-124, Birkhäuser, Basel, 1993.
33. PRZEGALINSKI, E.: Monoamines and the pathophysiology of seizure disorders. In Antiepileptic Drugs, ed. by H.-H. Frey and D. Janz, pp. 101-137, Springer, Berlin, 1985.
34. SCHNEIDER, L. S., TARIOT, P. N. AND GOLDSTEIN, B.: Therapy with 1-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 56: suppl., 750-756, 1994.
35. SPARKS, D. L. AND BUCKHOLTZ, N. S.: Combined inhibition of serotonin uptake and oxidative deamination attenuates audiogenic seizures in DBA/2J mice. Pharmacol. Biochem. Behav. 23: 753-757, 1985.
36. STROLIN BENEDETTI, M., MARRARI, P., COLOMBO, M., CASTELLI, M. G., ARAND, M., OESCH, F. AND DOSTERT, P.: The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J. Pharm. Pharmacol. 46: 814-819, 1994.
37. SWINYARD, E. A., BROWN, W. C. AND GOODMAN, L. S.: Comparative assay of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. 106: 319-330, 1952.
38. SWINYARD, E. A.: Laboratory evaluation of antiepileptic drugs. Review of laboratory methods. Epilepsia 10: 107-119, 1969.
39. TRIMBLE, M. R.: Epilepsy and behaviour. Epilepsy Res. 10: 71-79, 1991.
40. WALKER, M. C., SHARIEF, M. K., SANDER, J. W. A. S., PATSALOS, P. N. AND SHORVON, S. D.: Early experience with ucb LO59 in refractory epilepsy. Epilepsia 35: suppl.7, 76, 1994.
41. WESSEL, K. AND SZELENYI, I.: Selegiline: An overview of its role in the treatment of Parkinson's disease. Clin. Invest. 70: 459-462, 1992.
42. YOUDIM, M. B. H. AND FINBERG, J. P. M.: Pharmacological actions of 1-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clin. Pharmacol. Ther. 56: suppl., 725-733, 1994.
43. Yu, P. H.: Pharmacological and clinical implications of MAO-B inhibitors. Gen. Pharmacol. 25: 1527-1539, 1994.